Literature DB >> 667872

Radionuclide angiography for the evaluation of anthracycline therapy.

J W Kennedy, S G Sorensen, J L Ritchie, E D Folland, G W Hamilton.   

Abstract

A sensitive and reproducible method to noninvasively monitor cardiac function in patients receiving anthracycline therapy is badly needed. The radionuclide ejection fraction (EFrn) appears to be a suitable technique to provide this hemodynamic information. This paper describes the technique for determining the left ventricular EFrn with the use of technetium99m-labeled rbcs, a gamma scintillation camera, and a dedicated computer. The comparison of radionuclide and radiographic contrast EFrn showed a high correlation ( r = 0.84) in 30 patients.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 667872

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

1.  Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.

Authors:  D A Vorobiof; M Iturralde; G Falkson
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 2.  Adriamycin (doxorubicin) cardiotoxicity: a review.

Authors:  R T Chlebowski
Journal:  West J Med       Date:  1979-11

3.  A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.

Authors:  D I Jodrell; I E Smith; J L Mansi; M C Pearson; G Walsh; S Ashley; H D Sinnett; J A McKinna
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

Review 4.  Advanced Imaging Modalities to Monitor for Cardiotoxicity.

Authors:  Andreas Seraphim; Mark Westwood; Anish N Bhuva; Tom Crake; James C Moon; Leon J Menezes; Guy Lloyd; Arjun K Ghosh; Sarah Slater; Heather Oakervee; Charlotte H Manisty
Journal:  Curr Treat Options Oncol       Date:  2019-08-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.